Circulating miR-26a, miR-106b, miR-107 and miR-133b stratify hepatocellular carcinoma patients according to their response to transarterial chemoembolization.
Hepatocellular carcinoma
Prognostic markers
Serum microRNAs
TACE response
Journal
Clinical biochemistry
ISSN: 1873-2933
Titre abrégé: Clin Biochem
Pays: United States
ID NLM: 0133660
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
22
08
2018
revised:
09
11
2018
accepted:
10
01
2019
pubmed:
18
1
2019
medline:
19
3
2019
entrez:
18
1
2019
Statut:
ppublish
Résumé
A number of hepatocellular carcinoma (HCC) patients have developed resistance against transcatheter arterial chemoembolization (TACE) treatment. In this study, we aimed to develop a panel of microRNAs (miRs) biomarkers to predict clinical outcomes in HCC patients after TACE treatment. The expression level of twenty miRs was evaluated in FFPE tissues collected from 33 HCC patients. We selected four differentially expressed miRs in TACE-responders versus non-responders and re-assessed their expression in 51 serum samples. The expressions of miRs associated with overall survival (OS), progression-free survival (PFS), and treatment outcomes were investigated. The diagnostic accuracy of these miRs in predicting patients' response to TACE was also evaluated. The baseline of miR-106b, miR-107 and miR-133b was significantly elevated (p < .001) in sera of TACE-responders while miR-26a was elevated (p < .001) in non-responders. miR-26a and miR-133b recorded the highest diagnostic performance as individual classifiers in response to TACE (AUC = 1.0 and 100% sensitivity and specificity). Intriguingly, miR-133b distinguished complete responders from partial responders and non-responders (AUC ≥ 0.90). The PFS was improved (p < .05) in the high expression group of miR-31, miR-200b, miR-133b and miR-181a over their low expression group. Circulating miR-133b, miR-26a, miR-107 and miR-106 in serum are potential candidates to be utilized as prognostic biomarkers for predication of TACE treatment outcomes in HCC patients.
Sections du résumé
BACKGROUND
BACKGROUND
A number of hepatocellular carcinoma (HCC) patients have developed resistance against transcatheter arterial chemoembolization (TACE) treatment. In this study, we aimed to develop a panel of microRNAs (miRs) biomarkers to predict clinical outcomes in HCC patients after TACE treatment.
METHODS
METHODS
The expression level of twenty miRs was evaluated in FFPE tissues collected from 33 HCC patients. We selected four differentially expressed miRs in TACE-responders versus non-responders and re-assessed their expression in 51 serum samples. The expressions of miRs associated with overall survival (OS), progression-free survival (PFS), and treatment outcomes were investigated. The diagnostic accuracy of these miRs in predicting patients' response to TACE was also evaluated.
RESULTS
RESULTS
The baseline of miR-106b, miR-107 and miR-133b was significantly elevated (p < .001) in sera of TACE-responders while miR-26a was elevated (p < .001) in non-responders. miR-26a and miR-133b recorded the highest diagnostic performance as individual classifiers in response to TACE (AUC = 1.0 and 100% sensitivity and specificity). Intriguingly, miR-133b distinguished complete responders from partial responders and non-responders (AUC ≥ 0.90). The PFS was improved (p < .05) in the high expression group of miR-31, miR-200b, miR-133b and miR-181a over their low expression group.
CONCLUSION
CONCLUSIONS
Circulating miR-133b, miR-26a, miR-107 and miR-106 in serum are potential candidates to be utilized as prognostic biomarkers for predication of TACE treatment outcomes in HCC patients.
Identifiants
pubmed: 30653948
pii: S0009-9120(18)30919-6
doi: 10.1016/j.clinbiochem.2019.01.002
pmc: PMC6397777
mid: NIHMS1519164
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
45-52Subventions
Organisme : NCI NIH HHS
ID : R21 CA194750
Pays : United States
Informations de copyright
Copyright © 2019 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
Références
Hepatology. 2002 May;35(5):1164-71
pubmed: 11981766
Lancet. 2002 May 18;359(9319):1734-9
pubmed: 12049862
Cancer. 1991 Jan 1;67(1):81-6
pubmed: 1845939
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Eur J Cancer Care (Engl). 2009 Sep;18(5):492-9
pubmed: 19453695
Asian Pac J Cancer Prev. 2009 Jan-Mar;10(1):3-16
pubmed: 19469617
AJR Am J Roentgenol. 2009 Dec;193(6):1665-71
pubmed: 19933662
JAMA. 2010 Nov 17;304(19):2154-60
pubmed: 21081728
Curr Opin Mol Ther. 2010 Dec;12(6):695-702
pubmed: 21154161
Mol Carcinog. 2013 Apr;52(4):297-303
pubmed: 22213236
J Hepatol. 2012 Apr;56(4):908-43
pubmed: 22424438
BMC Infect Dis. 2013 Jun 24;13:288
pubmed: 23799878
J Egypt Natl Canc Inst. 2013 Sep;25(3):143-50
pubmed: 23932751
PLoS One. 2014 Oct 02;9(10):e109347
pubmed: 25275448
Biomed Res Int. 2015;2015:649750
pubmed: 25811030
Cell Physiol Biochem. 2015;37(1):276-83
pubmed: 26305026
Drug Des Devel Ther. 2015 Sep 16;9:5225-35
pubmed: 26396496
J Gastroenterol Hepatol. 2017 Jan;32(1):199-207
pubmed: 27194671
Oncotarget. 2016 Aug 16;7(33):53820-53836
pubmed: 27462777
Liver Int. 2017 Feb;37(2):271-279
pubmed: 27473646
Sci Rep. 2016 Oct 31;6:36104
pubmed: 27796321
Oncotarget. 2017 Jan 31;8(5):8775-8784
pubmed: 28060739
Medicine (Baltimore). 2017 Jan;96(2):e5642
pubmed: 28079796
Liver Cancer. 2017 Feb;6(2):113-125
pubmed: 28275578
World J Gastroenterol. 2017 May 28;23(20):3713-3720
pubmed: 28611524
Sci Rep. 2017 Jul 3;7(1):4511
pubmed: 28674420
AJR Am J Roentgenol. 2017 Oct;209(4):722-732
pubmed: 28705059
Clin Res Hepatol Gastroenterol. 2017 Sep;41(4):e51-e62
pubmed: 28750770
Oncotarget. 2017 May 8;8(32):52983-52994
pubmed: 28881788
JAMA Oncol. 2017 Dec 1;3(12):1683-1691
pubmed: 28983565
Oncotarget. 2017 Jul 26;8(41):70172-70182
pubmed: 29050269
Oncotarget. 2017 Sep 14;8(46):80666-80678
pubmed: 29113334
J Korean Med Sci. 2018 Jan 01;33(1):e6
pubmed: 29215815
Oncotarget. 2017 Nov 1;8(65):108810-108824
pubmed: 29312570